APTO [NASD]
Aptose Biosciences Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own20.40% Shs Outstand92.23M Perf Week10.42%
Market Cap93.49M Forward P/E- EPS next Y-0.69 Insider Trans2.42% Shs Float87.29M Perf Month-12.50%
Income-60.60M PEG- EPS next Q-0.13 Inst Own35.10% Short Float0.73% Perf Quarter-13.22%
Sales- P/S- EPS this Y-8.70% Inst Trans0.81% Short Ratio1.45 Perf Half Y-61.96%
Book/sh0.71 P/B1.48 EPS next Y-3.10% ROA-67.60% Target Price- Perf Year-79.61%
Cash/sh0.78 P/C1.35 EPS next 5Y- ROE-74.30% 52W Range0.90 - 5.78 Perf YTD-22.22%
Dividend- P/FCF- EPS past 5Y8.10% ROI- 52W High-81.84% Beta1.53
Dividend %- Quick Ratio9.80 Sales past 5Y- Gross Margin- 52W Low16.67% ATR0.09
Employees41 Current Ratio9.80 Sales Q/Q- Oper. Margin- RSI (14)41.68 Volatility8.80% 8.00%
OptionableYes Debt/Eq0.00 EPS Q/Q31.80% Profit Margin- Rel Volume0.26 Prev Close1.05
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume441.03K Price1.05
Recom- SMA20-6.84% SMA50-12.37% SMA200-41.65% Volume0 Change0.00%
Oct-19-20Initiated Cantor Fitzgerald Overweight $10
Sep-22-20Initiated Alliance Global Partners Buy $12
Feb-20-20Initiated Maxim Group Buy $16
Feb-06-20Reiterated H.C. Wainwright Buy $6 → $9
Jan-09-20Initiated Piper Sandler Overweight $10
Mar-01-19Initiated RBC Capital Mkts Outperform $6
Nov-16-18Initiated B. Riley FBR Buy $5
Dec-13-17Reiterated H.C. Wainwright Buy
Oct-23-17Resumed ROTH Capital Buy $5
Sep-07-17Upgrade H.C. Wainwright Neutral → Buy $1 → $4
Jun-08-17Initiated Rodman & Renshaw Neutral $1
May-12-22 10:00AM  
May-09-22 04:01PM  
May-04-22 07:30AM  
May-03-22 07:30AM  
May-02-22 04:10PM  
Apr-25-22 07:30AM  
Apr-07-22 07:00AM  
Mar-31-22 07:30AM  
Mar-22-22 04:01PM  
Mar-08-22 07:30AM  
Mar-01-22 07:30AM  
Feb-13-22 06:39AM  
Dec-31-21 01:50PM  
Dec-29-21 07:30AM  
Dec-28-21 09:38AM  
Dec-21-21 09:38AM  
Dec-20-21 07:30AM  
Dec-16-21 09:14AM  
Dec-15-21 04:09AM  
Dec-14-21 07:38AM  
Dec-13-21 04:30PM  
Dec-10-21 10:17AM  
Dec-09-21 11:18AM  
Dec-08-21 09:38AM  
Nov-29-21 07:30AM  
Nov-26-21 10:07AM  
Nov-24-21 10:17AM  
Nov-22-21 04:02PM  
Nov-11-21 04:01PM  
Nov-04-21 09:00AM  
06:00AM  
Oct-26-21 07:30AM  
Oct-25-21 08:00AM  
Aug-30-21 07:30AM  
Aug-19-21 10:47AM  
Aug-18-21 10:05AM  
Aug-06-21 12:00PM  
10:00AM  
Aug-03-21 04:01PM  
Aug-02-21 09:45AM  
01:47AM  
Jul-26-21 05:20PM  
12:03PM  
Jul-20-21 04:01PM  
Jul-19-21 06:52PM  
Jun-11-21 02:17PM  
07:55AM  
Jun-01-21 04:30PM  
May-27-21 07:30AM  
May-17-21 08:38AM  
May-12-21 07:30AM  
May-04-21 04:01PM  
02:30PM  
01:29AM  
Apr-26-21 04:02PM  
Apr-08-21 07:30AM  
Mar-24-21 12:25PM  
10:25AM  
Mar-23-21 04:01PM  
03:15PM  
Mar-16-21 07:30AM  
Mar-02-21 04:02PM  
Feb-08-21 10:11AM  
Feb-02-21 11:33PM  
Jan-06-21 09:24AM  
Dec-30-20 11:25AM  
07:26AM  
Dec-18-20 08:14PM  
Dec-16-20 01:31PM  
10:53AM  
Dec-15-20 09:57AM  
Dec-14-20 01:04PM  
12:59PM  
Dec-09-20 08:48AM  
Dec-07-20 09:27AM  
09:27AM  
09:13AM  
Dec-06-20 05:30PM  
Dec-04-20 08:59AM  
08:45AM  
Dec-03-20 10:04AM  
Dec-02-20 06:03PM  
03:52PM  
08:54AM  
Dec-01-20 08:55AM  
07:30AM  
Nov-17-20 10:00AM  
Nov-10-20 04:01PM  
03:15PM  
Nov-05-20 07:02AM  
Nov-04-20 10:17AM  
Oct-27-20 04:01PM  
Oct-20-20 10:26AM  
Oct-19-20 07:00AM  
Oct-14-20 09:52PM  
Sep-15-20 07:30AM  
Sep-09-20 07:30AM  
Sep-02-20 08:50AM  
Aug-28-20 06:53AM  
Aug-26-20 10:35AM  
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BURGER DENIS RDirectorDec 20Buy1.4510,00014,49031,671Dec 21 11:19 AM
Rice William G.Chair, President & CEODec 16Buy1.5213,18320,038343,252Dec 17 01:38 PM
PLATZER ERICHDirectorDec 16Buy1.38100,000137,900505,000Dec 20 04:33 PM
Rice William G.Chair, President & CEODec 15Buy1.1217,82219,961330,069Dec 15 01:48 PM
PLATZER ERICHDirectorDec 15Buy1.17270,000316,340405,000Dec 17 01:45 PM
Rice William G.Chair, President & CEONov 26Buy2.318,64319,965312,247Nov 29 11:53 AM
BURGER DENIS RDirectorNov 19Option Exercise2.045,41711,05121,671Nov 19 08:42 PM
Bejar RafaelSr. VP, Chief Medical OfficerNov 19Buy2.5610,00025,60010,000Nov 19 08:36 PM
Wilson Donald R. Jr.10% OwnerAug 05Sale2.6260,000157,2008,888,275Aug 05 09:54 PM
Wilson Donald R. Jr.10% OwnerAug 03Buy2.6557,199151,4068,948,275Aug 05 09:54 PM
Rice William G.Chair, President & CEOJul 02Buy3.296,08119,998303,604Jul 06 05:07 PM
Whitehead WarrenDirectorJun 22Sale3.249,60031,10415,000Jun 23 05:08 PM
Whitehead WarrenDirectorJun 21Sale3.3515,40051,59024,600Jun 23 05:08 PM